The roles of CHA2DS2-VASc score and blood inflammatory parameters in predicting the patency of saphenous vein grafts in patients with coronary artery bypass graft surgery

Main Article Content

Cihan Aydın
Mustafa Abanoz

Abstract

Objective: Coronary artery bypass graft (CABG) surgery is a common treatment method in which saphenous vein grafts (SVG) and arterial grafts are used together in severe coronary artery disease. The CHA2DS2-VASc score is used to predict thromboembolic events in nonvalvular atrial fibrillation as well as to predict prognosis in cardiovascular events.  In this study, we planned to research the relation between CHA2DS2-VASc score and postoperative SVG patency rates in patients undergoing CABG.


Materials and Methods: One hundred seventeen patients with angina after CABG surgery who underwent coronary angiography were analyzed retrospectively. Stenosis of 50% or more in at least one saphenous vein graft was accepted as saphenous vein graft disease (SVGD). We compared these patients in two groups concerning the presence of 50% or more stenosis in the SVG. These two groups were; Group 1 (n = 66); with saphenous vein graft disease, Group 2 (n = 51) without saphenous vein graft disease, respectively.


Results: A total of 117 patients participating in the study. Sixty-six patients in group 1 had SVGD (Mean age: 68,13±8,22, 60,6% male). Fifty-one patients in group 2 did not have SVGD (Mean age: 66,92±9,44, 72,5% male ). The mean CHA2DS2-VASc score was significantly higher in group 1 compared to group 2. [5 (2-7) vs.  2 (1-7), respectively, P<0,001]. As a result of multivariate analysis, CHA2DS2-VASc score (OR: 5,263, CI 95%: 2,176- 12,728, P<0.001) and SII (OR: 1,236, CI 95%: 1,120-2,955, P=0.007) were determined as independent predictors for predicting SVGD


Conclusion: In the light of the results we have found, the CHA2DS2-VASc score and SII, which are easy to calculate in daily practice, can help us in predicting SVGD.

Downloads

Download data is not yet available.

Article Details

How to Cite
Aydın, C., & Abanoz, M. (2021). The roles of CHA2DS2-VASc score and blood inflammatory parameters in predicting the patency of saphenous vein grafts in patients with coronary artery bypass graft surgery. Medical Science and Discovery, 8(10), 601–607. https://doi.org/10.36472/msd.v8i10.617
Section
Research Article

References

Bourassa MG, Enjalbert M, Campeau L, Lesperance J. Progression of atherosclerosis in coronary arteries and bypass grafts: ten years later. Am J Cardiol. 1984; 53:102C–107C.

Campeau L, Enjalbert M, Lesperance J, Bourassa MG, Kwiterovich P Jr, Wacholder S, Sniderman A. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311: 1329-32.

Cameron A, Kemp HG Jr, Green GE. Reoperation for coronary artery disease: 10 years of clinical follow-up. Circulation. 1988; 78: 158-62.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72.

Borovac JA, Kwok CS, Mohamed MO, Fischman DL, Savage M, Alraies C, et al. The Predictive Value of CHA2DS2-VASc Score on In-Hospital Death and Adverse Periprocedural Events Among Patients With the Acute Coronary Syndrome and Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention: A 10-Year National Inpatient Sample (NIS) Analysis. Cardiovasc Revasc Med. 2021;29:61-68

Aydın C, Engin M. The Value of Inflammation Indexes in Predicting Patency of Saphenous Vein Grafts in Patients With Coronary Artery Bypass Graft Surgery. Cureus 13(7): e16646

Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996;28(3):616-26.

Bourassa MG. Fate of venous grafts: the past, the present and the future. J Am Coll Cardiol. 1991: 17: 1081–1083

Galbut DL, Traad EA, Dorman MJ, DeWitt PL, Larsen PB, Kurlansky PA, et al. Seventeen-year experience with bilateral internal mammary artery grafts. Ann Thorac Surg 1990; 49:195-201.

Dewar LR, Jamieson WR, Janusz MT, Adeli-Sardo M, Germann E, MacNab JS, et al. Unilateral versus bilateral internal mammary revascularization. Survival and event- free performance. Circulation 1995; 92(9 Suppl): II8-13.

Gibson PH, Croal BL, Cuthbertson BH, Small GR, Ifezulike AI, Gibson G, et al. Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting. Am Heart J. 2007;154(5):995-1002.

Bagger JP, Zindrou D, Taylor KM. Leukocyte count: a risk factor for coronary artery bypass graft mortality. Am J Med. 2003; 115(8):660-663.

Pietersma A, Kofflard M, de Wit LE, Stijnen T, Koster JF, Serruys PW, et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation. 1995;91(5):1320-5.

Rahel BM, Visseren FL, Suttorp MJ, et al. Preprocedural serum levels of acutephase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res. 2003;60(1):136-140.

Oude Nijhuis MM, van Keulen JK, Pasterkamp G, Quax PH, de Kleijn DP. Activation of the innate immune system in atherosclerotic disease. Curr Pharm Des.2007; 13(10):983–994

Erdolu B, Engin M. The effect of mean platelet volume-to-lymphocyte ratio on symptom onset in patients with carotid artery stenosis. Turk J Vasc Surg 2021;30(1):7-12

Grau AJ, Boddy AW, Dukovic DA, Buggle F, Lichy C, Brandt T, Hacke W; CAPRIE Investigators. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke. 2004;35(5):1147-1152.

Cooper HA, Exner DV, Waclawiw MA, Domanski MJ. White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol.1999;84(3):252-257.

Sari I, Sunbul M, Mammadov C, Durmus E, Bozbay M, Kivrak T, et al. Relation of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio with coronary artery disease severity in patients undergoing coronary angiography. Kardiol Pol. 2015;73(12):1310-6.

Kurtul S, Sarli B, Baktir AO, Demirbas M, Saglam H, Doğan Y, et al. Neutrophil to lymphocyte ratio predicts SYNTAX score in patients with non-ST segment elevation myocardial infarction. Int Heart J. 2015;56(1):18-21.

Abanoz M, Engin M. The effect of the relationship between post-cardiotomy neutrophil/lymphocyte ratio and platelet counts on early major adverse events after isolated coronary artery bypass grafting. Turk Gogus Kalp Damar Cerrahisi Derg. 2021;29(1):36-44.

Kulik A, Voisine P, Mathieu P, Masters RG, Mesana TG, Le May MR, et al. Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. Ann Thorac Surg. 2011 Oct;92(4):1284-90; discussion 1290-1.

Turak O, Ozcan F, Isleyen A, Tok D, Sokmen E, Buyukkaya E, et al. Usefulness of the neutrophil-to-lymphocyte ratio to predict bare-metal stent restenosis. Am J Cardiol. 2012;110(10):1405-10.

Gurbuz O, Kumtepe G, Ozkan H, et al. Predictive value of neutrophil-lymphocyte ratio for long-term cardiovascular event following coronary artery bypass grafting. Braz J Cardiovasc Surg 2020;35:274–84.

Gungor H, Babu AS, Zencir C, Akpek M, Selvi M, Erkan MH, et al. Association of Preoperative Platelet-to-Lymphocyte Ratio with Atrial Fibrillation after Coronary Artery Bypass Graft Surgery. Med Princ Pract. 2017;26(2):164-168.

Huang J, Zhang Q, Wang R, Ji H, Chen Y, Quan X, et al. Systemic Immune-Inflammatory Index Predicts Clinical Outcomes for Elderly Patients with Acute Myocardial Infarction Receiving Percutaneous Coronary Intervention. Med Sci Monit. 2019;25:9690-9701.

Yang YL, Wu CH, Hsu PF, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest 2020;50:e13230.

Agus HZ, Kahraman S, Arslan C, Yildirim C, Erturk M, Kalkan AK, et al. Systemic immune-inflammation index predicts mortality in infective endocarditis. J Saudi Heart Assoc. 2020;32(1):58-64.

Erdoğan M, Erdöl MA, Öztürk S, Durmaz T. Systemic immune-inflammation index is a novel marker to predict functionally significant coronary artery stenosis. Biomark Med. 2020;14(16):1553-1561.

Gary T, Pichler M, Belaj K, Eller P, Hafner F, Gerger A, et al. Lymphocyte-to-monocyte ratio: a novel marker for critical limb ischemia in PAOD patients. Int J Clin Pract. 2014;68(12):1483-7.

Murat SN, Yarlioglues M, Celik IE, Kurtul A, Duran M, Kilic A, et al. The Relationship Between Lymphocyte-to-Monocyte Ratio and Bare-Metal Stent In-Stent Restenosis in Patients With Stable Coronary Artery Disease. Clin Appl Thromb Hemost. 2017; 23(3):235-240.

Orvin K, Bental T, Assali A, Lev EI, Vaknin-Assa H, Kornowski R.Usefulness of the CHA2DS2-VASC score to predict adverse outcomes in patients having percutaneous coronary intervention. Am J Cardiol 2016;117:1433–1438.

Capodanno D, Rossini R, Musumeci G, Lettieri C, Senni M, Valsecchi O, et al. Predictive accuracy of CHA2DS2-vasc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. Int J Cardiol 2015;199:319–325.

Bozbay M, Uyarel H, Cicek G, Oz A, Keskin M, Murat A, et al. CHA2DS2-vasc score predicts in-hospital and long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who were undergoing primary percutaneous coronary intervention. Clin Appl Thromb Hemost 2017; 23:132–138.

Taşolar H, Çetin M, Ballı M, Bayramoğlu A, Otlu YÖ, Türkmen S, Aktürk E. CHA2DS2-vasc-HS score in non-ST elevation acute coronary syndrome patients: assessment of coronary artery disease severity and complexity and comparison to other scoring systems in the prediction of in-hospital major adverse cardiovascular events. Anatol J Cardiol 2016; 16:742–748.

Chua SK, Lo HM, Chiu CZ, Shyu KG. Use of CHADS2 and CHA2DS2-vasc scores to predict subsequent myocardial infarction, stroke, and death in patients with acute coronary syndrome: data from Taiwan acute coronary syndrome full spectrum registry. PLoS One 2014; 9:e111167.

Kurtul A, Acikgoz SK. Validation of the CHA2DS2-vasc score in predicting coronary atherosclerotic burden and in-hospital mortality in patients with acute coronary syndrome. Am J Cardiol 2017; 120:8–14.

Ünal S, Açar B, Yayla Ç, Balci MM, Ertem A, Kara M, et al. Importance and usage of the CHA2DS2-vasc score in predicting acute stent thrombosis.Coron Artery Dis 2016; 27:478–482.

Ipek G, Onuk T, Karatas MB, Gungor B, Osken A, Keskin M, et al. CHA2DS2-vasc score is a predictor of no-reflow in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous intervention. Angiology 2016; 67:840–845.